medigraphic.com
Patología Revista Latinoamericana

2010, Número 2

<< Anterior Siguiente >>

Patol Rev Latinoam 2010; 48 (2)


Anormalidades vasculares en enfermedad inflamatoria intestinal en un grupo de niños

Acevedo GE, Serrano BC, Worona DL, Consuelo SA, Valencia MP

Idioma: Ingles.
Referencias bibliográficas: 53
Paginas: 93-99
Archivo PDF: 343.05 Kb.


RESUMEN

Objetivos: determinar si existen cambios vasculares en biopsias de colon de niños con enfermedad inflamatoria intestinal y describirlos.
Material y método: estudio retrospectivo de control de casos de 16 pacientes con enfermedad inflamatoria intestinal y 32 controles con sangrado intestinal realizado en el Hospital Infantil de México Federico Gómez. Los datos clínicos y los resultados de laboratorio se obtuvieron de los expledientes clínicos; se revisaron las biopsias de colon del Departamento de Patología. Se buscaron: vasculitis, endotelialitis y vasos con pavimentación de leucocitos.
Resultados: los vasos con pavimentación de leucocitos y la endotelialitis predominaron en los casos (p = 0.03 y p = 0.001), así como la endotelialitis con leucocitos polimorfonucleares (p ‹ 0.001) y con células mononucleares (p = 0.03); el daño vascular fue extenso en 12 casos y 5 controles (p ‹ 0.001); la intensidad global de daño vascular fue severa en 8 casos y 2 controles (p ‹ 0.001). En las biopsias de colon de seguimiento se encontraron daño vascular y datos de laboratorio de actividad.
Conclusiones: los cambios vasculares estuvieron presentes de manera significativa en pacientes con enfermedad inflamatoria intestinal; fueron parte de la patogénesis de daño a la mucosa y al mismo tiempo pueden ser indicadores de actividad de la enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Holmsquit L, Ahren C, Fallstrom SP. Relationship between results of laboratory test and inflammatory activity assessed by colonoscopy in children and adolescents with ulcerative colitis and Crohn’s disease. J Pediatr Gastroenterol Nutr 1989;9:187-193.

  2. Inflammatory bowel disease in children and adolescents: Recommendations for Diagnosis- The Porto Criteria. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2005;41:1-7.

  3. Medina Benítez E, Prieto Bozano G, Rodríguez Reynoso MF y col. Enfermedad inflamatoria intestinal. En Protocolos diagnósticos y terapéuticos en pediatría. Available at: http://www.aeped.es/protocolos/gastroentero/7.pdf. Accesed June, 2007

  4. Sykora J, Subrt I, Dédek P, et al. Cytokine tumor necrosis factor Y alpha A promoter gene polymorphism at position j308 GYA and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn’s disease. J Pediatr Gastroenterol Nutr 2006;42:479-487.

  5. Feeney MA, Murphy F, Clegg AJ, et al. A case-control study of childhood environmental risk factors for the development of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002;14:529-534.

  6. Griffiths AM, Leichtner A, Kirschnes BS, et al. Inflammatory bowel disease. In: Walker WA, Goulet O, Kleinman R. Pediatric Gastrointestinal Disease. 4th ed. USA: BC Decker, 2004;pp:789-872.

  7. Hyams JS, Markowitz HF. Enfermedad de Crohn y colitis ulcerosa. En: Wyllie R, Hyams J, editores. Gastroenterología Pediátrica. 2nd ed. México DF: McGraw-Hill, 2001;pp:455-489.

  8. Mamula P, Markowitz J, Baldassano R. Inflammatory bowel disease in early childhood and adolescents: special considerations. Gastroenterol Clin N Am 2003;32:967-995.

  9. Kolek A, Janout V, Tichy M, et al. The incidence of IBD is increasing among children 15 years old and younger in the Czech Republic. J Pediatr Gastroenterol Nutr 2004;38:362-363.

  10. Hildeebrand H, Finkel Y, Grahnquist L, et al. Changing pattern of pediatric IBD in Northern Stockholm 1990-2001. Gut 2003;52:1432-1434.

  11. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003;88:995-1000.

  12. Fragoso T, García E, García Pérez W y col. Estudio epidemiológico de la enfermedad inflamatoria intestinal en niños y adolescentes (Estudio multicéntrico). Rev Cub Pediatr 2002;74(3):195-202.

  13. Van der Zaag-Loonen HJ, Casparie M, Taminiau JAJ, et al. The incidence of pediatric inflammatory bowel disease in the Netherlands: 1999-2001. J Pediatr Gastroenterol Nutr 2004;38:302-330.

  14. Friedman AP. Epidemiology and the natural course of IBD. Gastroenterol Clin North Am 1999;28:255-281.

  15. Justinich CJ, Hyams JS. Enfermedad inflamatoria intestinal en niños y adolescents. Clin Endosc North Am 1994;1:39-55.

  16. Cosgrave M, Al Atia RF, Jenkins SR. The epidemiology of IBD. Arch Dis Child 1996;74:460-461.

  17. Jenkins HR. Enfermedad inflamatoria intestinal. Arch Dis Child 2001;84:435-437.

  18. Mamula P, Markowitz JE, Baldassano RN, et al. Inflammatory bowel disease in children 5 years of age and younger. Am J Gastroenterol 2002;97:2005-2019.

  19. Joossens S, Reinish W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122:1242-1247.

  20. Podolsky DK. Inflammatory Bowel Disease (1). NEJM 1991;325:928-937.

  21. Sands BE, Therapy of inflammatory bowel disease. Gastroenterology 2000;118;s68-s82.

  22. Piccarella D, Hurlbut P, Rottman J, et al. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhighCD4+ T cells. J Inmunol 1997;158:2099-2106.

  23. Reinshagen M, Egger B, Procaccino F, et al. Neuropeptides in inflammatory bowel disease: an update. Inflamm Bowel Dis 1997;3:303-313.

  24. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propia (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn’s disease LP cells manifest increases secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Inmunol 1996;157:1261-1270.

  25. Podolsky DK. Inflammatory bowel disease. NEJM 2002;347(6):417-429.

  26. Fenoglio-Preiser C, Noffsinger A, Stemmermann G, et al. Gastrointestinal pathology: an atlas and text. 3rd ed. Philadelphia: Lippincott, Williams and Wilkins, 2008. Chapter 11: Inflammatory bowel disease.

  27. Hyams JS, Mandel F, Ferry G, et al. Relationship of common laboratory parameters to the activity of Crohn’s disease in Children. J Pediatr Gastroenterol Nutr 1992; 14: 216-222.

  28. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National cooperative Crohn’s Disease study. Gastroenterology 1976;70:439-444.

  29. Wright JP, Marks IN, Parfitt A. A simple clinical index of Crohn’s disease activity- The Cape Town Index. S Afr Med J 1985;68:502-503.

  30. Talstad I, Gjone E. The disease activity of ulcerative colitis and Crohn’s disease. Scan J Gastroenterol 1976;11:403-408.

  31. Walmsley RS, Ayres RCS, Pounder RE, et al. A simple clinical Colitis Activity Index. Gut 1998;43:29-32.

  32. Kambe H, Yoshida T, Haraguchi Y, et al. Quantification of disease activity in patients with ulcerative colitis. J Clin Gastroenterol 1986;8:651-654.

  33. Seo M, Okada M, Yao T, et al. Evaluation of disease activity in patients with moderately active ulcerative colitis; comparison of a new activity index and Truelove and Witts. Am J Gastroenterol 1995;90:1759-1763.

  34. Ludwig J. Histopathology of the liver after transplantation. In: Maddrey WC, Sorrel MF, editors. Transplantation of the liver. Connecticut: Appleton and Lange, 1988;pp:274-289.

  35. Hatoum O, Binion D. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 2005;11:304-313.

  36. Kumar V, Abbas AK, Fausto NP. Robbins and Cotran. Texbook of pathology. 7th ed. Philadelphia: Elsevier Saunders, 2005;pp:846-851.

  37. Phillips J, Poucell S, Patterson J, et al. The Liver: An Atlas and Text of Ultrastructural Pathology. New York: Raven Press Books, 1987;pp:521-556.

  38. Kughathasan S, Judd RH, Hoffman RG, et al. Epidemiologic and clinical characteristics of children with early diagnosed inflammatory bowel disease in Wisconsin: a statewade population based-study. J Pediatr 2003;143:525-531.

  39. Koutroubakis IE, Tsiolakidou G, Kouroumalis EA. Inherited thrombophilia and thrombosis in inflammatory bowel disease. Am J Gastroenterol 2006;101:403.

  40. Coppi LC, Thomazzi SM, Ayrizono ML, et al. Comparative study of eosinophil chemotaxis, adhesion, and degranulation in vitro in ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 2007;13:211-218.

  41. Rubin P, Friedman S, Harpaz N, et al. Colonoscopic polipectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999;117:1295-1300.

  42. Wu T, Rezai B, Rashid A, et al. Genetic alterations and epithelial dysplasia in juvenile polyposis syndrome and sporadic juvenile polyps. Am J Pathol 1997;150: 939-947.

  43. Bond J. Polyp guide: diagnosis, treatment and surveillance for patients with colorectal polyps. Am J Gastroenterol 2000;95:3053-3063.

  44. Kiparissi F, Lindley K, Hill S, et al. Mucosal eosinophilia as a possible factor in the pathogenesis of inflammatory juvenile polyps. J Pediatr Gastroenterol Nutr 2006;42(5):E42-E43.

  45. Quintero-Hernández OJ, Heller-Rouassant S, Valencia-Mayoral P. Descripción de los cambios morfológicos de la mucosa colónica de los pacientes pediátricos con pólipos juveniles. Tesis. Hospital Infantil de México-Facultad de Medicina. Universidad Autónoma de México. Agosto 2006.

  46. Dubucquoi S, Janin A, Klein O, et al. Activated eosinophils and interleukin 5 expression in early recurrence of Crohn’s disease. Gut 1995;37(2):242-246.

  47. Hakansson L, Nielsen LS, Teder P. Measurement of neutrophil andeosinophil adhesion to E-selectin, VCAM-1, and ICAM-1 by the use of transfected fibroblast cell lines. J Immunol Methods 1994;176 (1):53-66. (Abstract)

  48. Van Dieren JM, Kuipers EJ, Samsom JN, et al. Revisiting the inmunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: Mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 2006;12:311-327.

  49. Oz HZ, Ray M, Chen TS, et al. Efficacy of a transforming growth factor β2 containing nutritional support formula in murine model of IBD. J Am Coll Nutr 2004;23:220-226.

  50. Hahm KB, Ym YH, Parks TW, et al. Lost of transforming growth factor beta signaling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 2001;49:190-198.

  51. Koizumi M, King N, Lobb R, et al. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992;103:840-847.

  52. Toms C, Powrie F. Control of intestinal inflammation by regulatory T cells. Microbes Infect 2001;3:929-935.

  53. Koutroubakis IE, Sfiridaki A, Tsiolakidou G, et al. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm Bowel Dis 2007;13:410-417.




2020     |     www.medigraphic.com